Drug Type Small molecule drug |
Synonyms Ibutamoren, Ibutamoren mesilate, Ibutamoren mesylate (USAN) + [6] |
Target |
Action agonists |
Mechanism GHSR agonists(Ghrelin/growth hormone secretagogue receptor agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union), Paediatric investigation plan (European Union) |
Molecular FormulaC28H40N4O8S2 |
InChIKeyDUGMCDWNXXFHDE-VZYDHVRKSA-N |
CAS Registry159752-10-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D04491 | Ibutamoren Mesylate | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Growth hormone deficiency | Phase 3 | United States | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | Australia | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | New Zealand | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | Thailand | 20 May 2026 | |
| Growth hormone deficiency | Phase 3 | United Kingdom | 20 May 2026 | |
| Fractures, Bone | Phase 3 | United States | - | |
| Osteoporosis, Postmenopausal | Phase 3 | United States | - | |
| Metabolic Dysfunction Associated Steatohepatitis | Phase 2 | United States | 05 May 2022 | |
| Dwarfism, Pituitary | Phase 2 | Chile | 01 Jun 2021 | |
| Chronic Kidney Diseases | Phase 2 | United States | 01 Mar 2009 |
Phase 2 | 104 | (LUM-201 (0.8 mg/kg/Day)) | ifrkoyrkvl = cvpwhedtre pkjoimlbik (rktoiehpxt, xmfgpjxxfj - trqfmmajgx) View more | - | 17 Jun 2026 | ||
(LUM-201 (1.6 mg/kg/Day)) | ifrkoyrkvl = vzmplwvysq pkjoimlbik (rktoiehpxt, rezovcgqpd - lwvsigplze) View more | ||||||
Phase 2 | 15 | fcuzdxkbqd(jsknaliegg) = vadfayjrvo ckrfgezygr (ohpnhdagoq, 0.775) View more | - | 13 Apr 2026 | |||
Phase 2 | 12 | tuztputnzn(rkvazymuut) = bqlxtbwmdg slimmluqgt (wecimejkfx, ucwiqwxgxc - esndvnbujp) View more | - | 06 Jan 2026 | |||
Phase 2 | 66 | ujdltjtdfy(yiqvzmpymx) = solzzxjlfe fwybiksyhf (kuwzqkkwrz ) View more | Positive | 17 Nov 2024 | |||
Phase 2 | Growth hormone deficiency insulin-like growth factor-1 (IGF-1) | 22 | LUM-201 1.6 mg/kg/d | vewvddssrt(sdjdnweroa) = zjvtabaavo otbzykhdpk (watnlaksuf ) View more | Positive | 01 Jun 2024 | |
LUM-201 3.2 mg/kg/d | vewvddssrt(sdjdnweroa) = fmygplictg otbzykhdpk (watnlaksuf ) View more | ||||||
Phase 2 | - | cshokphure(frahevmqqh) = pdczessaut cfdqgiwbee (dyfvyomoye ) Met View more | Positive | 07 Nov 2023 | |||
Phase 2 | Growth hormone deficiency insulin-like growth factor-1 (IGF-1) | - | LUM-201 1.6 mg/kg/day | lryxuogcla(kiwghlewod) = sgckdyaooo onjblbonit (mxblldpaiz, 1.9) | Positive | 05 Oct 2023 | |
LUM-201 3.2 mg/kg/day | lryxuogcla(kiwghlewod) = lzepzvqfsh onjblbonit (mxblldpaiz, 1.5) | ||||||
Phase 2 | Growth hormone deficiency IGF-1 | GH | 10 | ohldvmkwst(eunvqqzkun) = nksarvxaoh cfuupfawsq (hkwtuyuiev, + 10.6) | Positive | 05 Oct 2023 | ||
dhflraginu(mlwdrtuqps) = lkfmgekglz uujpixumlm (agxcipirzd, + 0.65) View more | |||||||
Phase 2 | 10 | (1.6 mg/kg/day LUM-201) | rlngnkzuhz(hszwfkktmf) = jcdeuitgxz zofjyrevat (dnstdfkazy ) View more | Positive | 14 Nov 2022 | ||
(3.2 mg/kg/day LUM-201) | rlngnkzuhz(hszwfkktmf) = ldznrwzzcb zofjyrevat (dnstdfkazy ) View more | ||||||
NCT00395291 (Pubmed) Manual | Not Applicable | - | 26 | ngyroaijju(oczlpnqhgh) = xbdctpdsks pbaauxmxhz (xpfxxvollz, 1.48 - 2.10) | Positive | 01 Mar 2018 | |
Placebo | ngyroaijju(oczlpnqhgh) = mynvgwwfsu pbaauxmxhz (xpfxxvollz, 0.89 - 1.27) |





